Effect of dendritic cell vaccine therapy on lymphocyte subpopulation in refractory primary brain tumor.
Indian J Cancer
;
2015 Oct-Dec; 52(4): 587-589
Artigo
em Inglês
| IMSEAR
| ID: sea-176290
ABSTRACT
BACKGROUND:
Dendritic cell (DC)‑based immunotherapy has the potential to induce an antitumor response within the immunologically privileged brain.AIMS:
The aim of this study was to evaluate the short‑term effect of DC vaccine therapy on lymphocyte subsets in patients with refractory primary brain tumor. MATERIALS ANDMETHODS:
Eighteen cases with refractory primary brain tumor who refused any treatment against tumor within 6 months of the therapy, were referred to one medicine center, from January 2011 to October 2012. All patients received 1 × 107 tumor lysate–pulsed DC vaccinations both intradermal injection and intravenous infusion 3 times/week.RESULTS:
There were increases of lymphocytes CD8+ (P = 0.002) and CD56+ (P = 4.207E‑10), but no change of lymphocytes CD3+ (P = 0.651). Six patients were positive response of delayed‑type hypersensitivity. There were improving of appetite in 14 cases and increasing of physical strength 17 cases.CONCLUSIONS:
DC vaccine has the potential for inducing an immune cytotoxic effect directed toward tumor cells.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Idioma:
Inglês
Revista:
Indian J Cancer
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS